Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
---|---|
Enthalten in: |
Journal of neuroImmune pharmacology - 15(2020), 3 vom: Sept., Seite 349-349 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Patel, Tejas K. [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: |
---|
doi: |
10.1007/s11481-020-09940-9 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR040905292 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR040905292 | ||
003 | DE-627 | ||
005 | 20230520011657.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s11481-020-09940-9 |2 doi | |
035 | |a (DE-627)SPR040905292 | ||
035 | |a (SPR)s11481-020-09940-9-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
084 | |a 44.38 |2 bkl | ||
084 | |a 44.90 |2 bkl | ||
100 | 1 | |a Patel, Tejas K. |e verfasserin |4 aut | |
245 | 1 | 0 | |a Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
700 | 1 | |a Barvaliya, Manish |e verfasserin |4 aut | |
700 | 1 | |a Kevadiya, Bhavesh D. |e verfasserin |4 aut | |
700 | 1 | |a Patel, Parvati B. |e verfasserin |4 aut | |
700 | 1 | |a Bhalla, Hira Lal |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of neuroImmune pharmacology |d Boston, MA [u.a.] : Springer, 2006 |g 15(2020), 3 vom: Sept., Seite 349-349 |w (DE-627)SPR020022093 |w (DE-600)2227405-4 |x 1557-1904 |7 nnns |
773 | 1 | 8 | |g volume:15 |g year:2020 |g number:3 |g month:09 |g pages:349-349 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11481-020-09940-9 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OPC-PHA | ||
912 | |a SSG-OPC-ASE | ||
936 | b | k | |a 44.38 |q ASE |
936 | b | k | |a 44.90 |q ASE |
951 | |a AR | ||
952 | |d 15 |j 2020 |e 3 |c 09 |h 349-349 |